2+ day, 19+ hour ago   (293+ words) Sept 10 (Reuters) – Biohaven said on Thursday the U.S. FDA had imposed a partial clinical hold, pausing new patient enrollment in trials of its experimental epilepsy drug ​after rodent findings, sending its shares down more than ‌15% in early trading. • The U....

4+ day, 14+ hour ago   (317+ words) Sept 8 (Reuters) – Shares of Dyne Therapeutics and Sarepta slumped on Tuesday after Novartis’ treatment for a muscle-wasting disorder failed in a trial, fueling investor concerns ​about the prospects of similar therapies for the tough-to-treat ‌rare disease. Dyne’s stock led declines…...

4+ day, 18+ hour ago   (66+ words) WTVB AstraZeneca’s cancer drug combo hits main survival goal in late-stage trial Sept 8 (Reuters) – AstraZeneca said ​on Tuesday its cancer drug ​Imfinzi ⁠combined with ⁠Amgen’s targeted immunotherapy Imdelltra ​significantly ⁠improved ⁠overall survival ​in ​first-line extensive-stage small cell lung ⁠cancer in…...

5+ day, 1+ hour ago   (176+ words) ZURICH, Sept 8 (Reuters) – Swiss drugmaker Novartis on Tuesday said a late-stage study assessing drug del-desiran’s ​impact on myotonic dystrophy, a form ‌of muscle wasting, had not met its target on a key metric, but reaffirmed its sales guidance through 2030. Novartis…...

5+ day, 2+ hour ago   (652+ words) NEW DELHI, Sept 8 (Reuters) – India is witnessing an unprecedented food safety crackdown, with regulators forcing many local eateries and branded restaurants to suspend operations, while a push for front-of-pack warning labels has rattled the country’s more than $100 billion packaged food…...

5+ day, 19+ hour ago   (191+ words) Sept 7 (Reuters) – Novo Nordisk said on Monday it had halted two additional trials of its ​experimental cardiovascular drug ziltivekimab, further ‌denting the Danish drugmaker’s efforts to diversify beyond its blockbuster obesity and diabetes franchise. In July, Novo said ziltivekimab failed…...

1+ week, 1+ day ago   (464+ words) By Christy Santhosh and Bhanvi Satija Sept 4 (Reuters) – Novartis said on Friday its experimental drug pelacarsen did not cut the risk of major heart attacks and strokes in patients with a genetic risk factor in a late-stage trial, marking a…...

1+ week, 4+ day ago   (311+ words) Sept 1 (Reuters) – Britain’s medicines regulator on Tuesday suspended the use and sale of Amgen’s rare-disease drug Tavneos to new patients, saying the main study supporting its approval was ​unreliable. Sold as Avacopan Vifor in Britain by CSL Vifor, ‌the drug…...

1+ week, 4+ day ago   (117+ words) Sept 1 (Reuters) – Switzerland’s Roche will pay $75 million upfront to Simcere Pharmaceutical Group ​for rights to an ‌experimental blood cancer drug, the Chinese drugmaker said Tuesday. • SIM0660 targets B-cell malignancies, Simcere said ‌in ​a filing ⁠to the Hong ⁠Kong stock exchange. • B…...

1+ week, 4+ day ago   (320+ words) Sept 1 (Reuters) – Novartis said on Tuesday it paused eight clinical trials of an experimental cell therapy, called rap-cel, targeting autoimmune and neurological disorders in late August, after ​three patients died. The halt was implemented on August 24 ‌after Novartis was notified…...